Eris Lifesciences Limited (“Eris Lifesciences” or the “Company”) (BSE: 540596; NSE: ERIS), a leading Indian branded formulations manufacturing company, today announced its earnings for the quarter and nine months ended December 31, 2025.
Q3 and 9M FY2026 Key Financial Highlights:
· The DBF business reported revenue growth of 10% YoY in Q3 FY26 and 9M FY26
· Consolidated Revenue grew 11% YoY during Q3 and 8.4% YoY 9M FY26
· Consol EBITDA was Rs. 282 Cr in Q3, margin of 34.9% and Rs. 847 Cr with a margin of 35.7% during 9M FY26
· Adjusted PAT* was Rs. 120 Cr in Q3 FY26, a PAT margin of 14.9%. For 9M FY26, Adj PAT* was Rs. 380 Cr, with a 16.0% margin
· Net debt as of December 30, 2025, stood at Rs. 2,270 Cr
Commenting on the results, Mr. Amit Bakshi, Chairman & Managing Director of Eris Lifesciences Ltd, said, “I am pleased to share that, as per our expectation, we have reached a 25% share in the RHI cartridges market in Dec-25. Eris now services one in every four Indian patients on RHI cartridges. We are well on track to achieve a dominant position in the overall Insulins market including Glargine and several analogues. We are gearing up for our GLP-1 launch in due course and are also launching Esaxerenone, a potential game changer in hypertension management, thereby strengthening our cardiovascular franchise.”
Krishnakumar Vaidyanathan, Executive Director & Chief Operating Officer added, “Our core Domestic Branded Formulations business is tracking to deliver a 12% revenue growth in FY26 with a 37% EBIDTA margin. Our capital investments in Injectables, Insulins, MABs and GLP-1 in-sourcing continue in line with our guidance. We have strong visibility on FY27 shaping up as a breakout year for our international business with significant contribution expected from our CDMO clients in regulated markets.”
